Endocrine Abstracts

Objectives: Endogenous Cushing’s Syndrome (CS) is a rare, chronic condition that results in high morbidity, caused by prolonged exposure to elevated levels of circulating free cortisol levels. Osilodrostat, a newly approved steroidogenesis inhibitor, has been shown to achieve fast and high rates of cortisol normalization, improving manifestations of hypercortisolism in patients with Cushing’s Disease (CD), a form of CS. We evaluated relative complete response (CR) ou...

Background: Bilateral adrenalectomy (BLA) is a treatment option for patients suffering from endogenous Cushing syndrome (CS). It consists of the surgical removal of both adrenal glands. Even though BLA offers immediate control of cortisol excess, given the risk of adrenal insufficiency, it requires life-long glucocorticoid and mineral corticoid replacement. It may lead to perioperative and long-term complications which affect patients’ quality of life (QoL). Health state ...

Objectives: Endogenous Cushing’s syndrome (CS) is a rare, chronic condition that results in high morbidity, caused by prolonged exposure to elevated levels of circulating free cortisol. A previous comparative analysis showed osilodrostat increases the odds of complete response (CR; mean urinary free cortisol [mUFC] ≤ 1.0 x the upper limit of normal) at Weeks 12 and 36 vs metyrapone1; however, analyses were limited by small osilodrostat effective sample si...